New Data Show Durable Efficacy of Acalabrutinib in CLL
The body of research around acalabrutinib is becoming quite advanced, allowing clinicians to feel confident when treating patients.
In an interview with Pharmacy Times, Niko Andre, MD, PhD, global franchise head of hematology and immuno-oncology at AstraZeneca, discussed exciting new findings being presented at the American Society of Hematology 2021 Annual Meeting about the durable efficacy of acalabrutinib in chronic lymphocytic leukemia (CLL).
In the interview, Andre said the body of research around acalabrutinib is becoming quite advanced, allowing clinicians to feel confident when treating patients. He also discussed adverse effects associated with acalabrutinib and how pharmacists can approach the management of treatment with acalabrutinib.
